(Reuters) - Export-focused Indian drugmaker Dr. Reddy’s Laboratories Ltd said it was in talks with a U.S. regulator over allegations it violated packaging rules for some prescription drugs sold there between 2008 and 2012.
The allegations by the U.S. government’s Consumer Product Safety Commission (CPSC) are the latest in a series of regulatory troubles facing Indian pharmaceutical firms in their biggest export market, the United States.
In a U.S. stock exchange filing this week, Dr Reddy’s said the CPSC planned to seek civil penalties against the company for allegedly violating rules intended to prevent children from ingesting harmful substances.
Help employers find you! Check out all the jobs and post your resume.
